Please use this identifier to cite or link to this item:
10.3748/wjg.v21.i41.11636
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kalnina, Zane | - |
dc.contributor.author | Meistere, Irena | - |
dc.contributor.author | Kikuste, Ilze | - |
dc.contributor.author | Tolmanis, Ivars | - |
dc.contributor.author | Zayakin, Pawel | - |
dc.contributor.author | Line, Aija | - |
dc.date.accessioned | 2022-02-07T13:50:02Z | - |
dc.date.available | 2022-02-07T13:50:02Z | - |
dc.date.issued | 2015-11-07 | - |
dc.identifier.citation | Kalnina , Z , Meistere , I , Kikuste , I , Tolmanis , I , Zayakin , P & Line , A 2015 , ' Emerging blood-based biomarkers for detection of gastric cancer ' , World Journal of Gastroenterology , vol. 21 , no. 41 , pp. 11636-11653 . https://doi.org/10.3748/wjg.v21.i41.11636 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/7561 | - |
dc.description | Publisher Copyright: © 2015 Baishideng Publishing Group Inc. All rights reserved. | - |
dc.description.abstract | Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality, and for improving the management of patients with gastric cancer (GC). Blood-based biomarker assays for the detection of early-stage GC could be of great relevance both for population-wide or risk groupbased screening programs, while circulating biomarkers that reflect the genetic make-up and dynamics of the tumor would allow monitoring of treatment efficacy, predict recurrences and assess the genetic heterogeneity of the tumor. Recent research to identify blood-based biomarkers of GC has resulted in the identification of a wide variety of cancer-associated molecules, including various proteins, autoantibodies against tumor associated antigens, cell-free DNA fragments, mRNAs and various non-coding RNAs, circulating tumor cells and cancer-derived extracellular vesicles. Each type of these biomarkers provides different information on the disease status, has different advantages and disadvantages, and distinct clinical usefulness. In the current review, we summarize the recent developments in blood-based GC biomarker discovery, discuss the origin of various types of biomarkers and their clinical usefulness and the technological challenges in the development of biomarker assays for clinical use. | en |
dc.format.extent | 18 | - |
dc.format.extent | 1255766 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | World Journal of Gastroenterology | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Autoantibodies | - |
dc.subject | Biomarker | - |
dc.subject | Cell-free DNA | - |
dc.subject | Cell-free RNA | - |
dc.subject | Extracellular vesicles | - |
dc.subject | Gastric cancer | - |
dc.subject | Liquid biopsy | - |
dc.subject | Proteomics | - |
dc.subject | 3.1 Basic medicine | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Gastroenterology | - |
dc.subject | SDG 3 - Good Health and Well-being | - |
dc.title | Emerging blood-based biomarkers for detection of gastric cancer | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.3748/wjg.v21.i41.11636 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=84947224850&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Emerging_blood_based_biomarkers.pdf | 1.23 MB | Adobe PDF | View/Open![]() |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.